Your Good Partner in Biology Research

  1. 首页
  2. 试剂盒
  3. 酶联免疫试剂盒
  4. Mouse Osteoprotegerin,OPG ELISA KIT

Mouse Osteoprotegerin,OPG ELISA KIT

  • 中文名称：
    小鼠骨保护素(OPG)酶联免疫试剂盒
  • 货号：
    CSB-E04693m
  • 规格：
    96T/48T
  • 价格：
    ￥3800/￥2500
  • 其他：

产品详情

  • 产品描述：
        TNFRSF11B（Tumor Necrosis Factor Receptor Superfamily Member 11B），也被称为骨保护素（Osteoprotegerin, OPG），是一种可溶性受体蛋白。它通过结合受体激活因子κB配体（RANKL）来抑制骨吸收过程，从而在骨代谢中发挥关键作用。此外，OPG还参与血管钙化、炎症和免疫功能等其他生物学过程。OPG的含量是调节骨吸收和形成的重要因素。在某些疾病中，OPG的过量或缺乏会导致骨疾病的发生，如骨质疏松症和肿瘤性骨病变。
        j9九游会登录入口首页生物所提供的Mouse Osteoprotegerin,OPG ELISA KIT属于ELISA检测试剂盒，采用双抗夹心法定量检测鼠血清、血浆、组织匀浆样本中的TNFRSF11B，其灵敏度为3.9 pg/mL，检测范围为15.6 pg/mL-1000 pg/mL。
     
  • 别名：
    Tnfrsf11b ELISA Kit; Ocif ELISA Kit; Opg ELISA Kit; Tumor necrosis factor receptor superfamily member 11B ELISA Kit; Osteoclastogenesis inhibitory factor ELISA Kit; Osteoprotegerin ELISA Kit
  • 缩写：
  • Uniprot No.：
  • 种属：
    Mus musculus (Mouse)
  • 样本类型：
    serum, plasma, tissue homogenates
  • 检测范围：
    15.6 pg/mL-1000 pg/mL
  • 灵敏度：
    3.9 pg/mL
  • 反应时间：
    1-5h
  • 样本体积：
    50-100ul
  • 检测波长：
    450 nm
  • 研究领域：
    Cell Biology
  • 测定原理：
    quantitative
  • 测定方法：
    Sandwich
  • 精密度：
    Intra-assay Precision (Precision within an assay): CV%<8%        
    Three samples of known concentration were tested twenty times on one plate to assess.    
    Inter-assay Precision (Precision between assays): CV%<10%        
    Three samples of known concentration were tested in twenty assays to assess.      
                   
  • 线性度：
    To assess the linearity of the assay, samples were spiked with high concentrations of mouse OPG in various matrices and diluted with the Sample Diluent to produce samples with values within the dynamic range of the assay.  
    　 Sample Serum(n=4)    
    1:5 Average % 87    
    Range % 83-90    
    1:10 Average % 102    
    Range % 98-106    
    1:20 Average % 85    
    Range % 81-89    
    1:40 Average % 97    
    Range % 93-100    
  • 回收率：
    The recovery of mouse OPG spiked to levels throughout the range of the assay in various matrices was evaluated. Samples were diluted prior to assay as directed in the Sample Preparation section.  
     
    Sample Type Average % Recovery Range    
    Serum (n=5) 85 81-89    
    EDTA plasma (n=4) 96 92-99    
                   
                   
  • 标准曲线：
    These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed.  
     
    pg/ml OD1 OD2 Average Corrected    
    1000 2.045 2.102 2.074 1.938    
    500 1.357 1.308 1.333 1.197    
    250 0.879 0.915 0.897 0.761    
    125 0.593 0.578 0.586 0.450    
    62.5 0.381 0.368 0.375 0.239    
    31.2 0.275 0.298 0.287 0.151    
    15.6 0.193 0.187 0.190 0.054    
    0 0.135 0.137 0.136 　    
  • 数据处理：
  • 货期：
    3-5 working days

产品评价

靶点详情

  • 最新研究进展：
    最近的研究表明，TNFRSF11B在骨代谢和肿瘤的发生中起着重要作用。
  • 功能：
    Acts as decoy receptor for TNFSF11/RANKL and thereby neutralizes its function in osteoclastogenesis. Inhibits the activation of osteoclasts and promotes osteoclast apoptosis in vitro. Bone homeostasis seems to depend on the local ratio between TNFSF11 and TNFRSF11B. May also play a role in preventing arterial calcification. May act as decoy receptor for TNFSF10/TRAIL and protect against apoptosis. TNFSF10/TRAIL binding blocks the inhibition of osteoclastogenesis.
  • 基因功能参考文献：
    1. lactation increases physiological maxillary bone remodeling and orthodontic tooth movement, and both require activation of RANK/RANKL/OPG system PMID: 29382610
    2. Hdac3-depletion in osteoblasts increases expression of Opg, subsequently preserving insulin sensitivity. PMID: 28840938
    3. Epithelial rests of Malassez may be associated with root resorption via OPG, thus helping to explain the mechanism underlying root resorption. PMID: 29644561
    4. findings demonstrate that mTORC1 activation-stimulated RANKL expression in B cells is sufficient to induce bone loss and osteoporosis. The study also established a link between mTORC1 and the RANKL/OPG axis via negative regulation of beta-catenin. PMID: 26825871
    5. RANK/RANKL signaling is involved in the androgen deprivation therapy-induced acceleration of bone metastasis in castration-insensitive prostate cancer and is inhibited by osteoprotegerin to prevent bone metastasis. PMID: 28373003
    6. endocortical resorption is driven by reduced OPG rather than elevated RANKL expression PMID: 27460899
    7. Diabetes significantly increased OPG and the OPG/TRAIL ratio expression in the aorta, while dyslipidemia was the major determinant of the changes observed in the heart, where it significantly increased OPG and reduced TRAIL expression, thus increasing cardiac OPG/TRAIL ratio. PMID: 28070143
    8. These discoveries strongly suggest that Heparan Sulfate plays an active role in regulating OPG-RANKL interaction and osteoclastogenesis. PMID: 27697839
    9. OPG plays an important role in regulating bone marrow mesenchymal stem cells differentiation and bone marrow adipogenesis. PMID: 27898403
    10. These data suggested that OPG played an important role in maintaining the homeostasis of articular cartilage of femoral head. PMID: 27541035
    11. Data show that p38alpha mitogen-activated protein kinase (MAPK) in paired related homeobox 1 protein (Prx1+) bone marrow-derived mesenchymal stromal cells acts to preserve the bone by sustaining osteoprotegerin (OPG) production. PMID: 26947973
    12. OPG expression in chondrocyte increases bone mass in the proximal metaphysis of tibiae through negative regulation of osteoclast formation. PMID: 26329493
    13. the generation of Rag2GFP+ regulatory T cells is unaltered in Tnfrsf11b(-/-) mice PMID: 26254339
    14. identify osteoprotegerin as a HIF target gene capable of directing osteoblast-mediated osteoclastogenesis to regulate bone homeostasis PMID: 25846796
    15. Osteoprotegerin is increased in metabolic syndrome and promotes adipose tissue proinflammatory changes. PMID: 24998520
    16. These results indicate that OPG derived either from the bone marrow or from the vessel wall is sufficient to slow down lesion progression and vascular calcification independent of bone turnover. PMID: 23990207
    17. High concentrations of alendronate decrease the expressions of OPG and RANKL in cultured osteoblasts. PMID: 23268391
    18. In a xenograft model, increased osteoprotegerin expression correlated with a delay to pathologic fracture suggesting a potential role for mTOR inhibitors in the treatment of neuroblastoma bone metastases. PMID: 23331792
    19. Coptisine inhibits RANKL-induced NF-kappaB phosphorylation in osteoclast precursors and suppresses function through the regulation of RANKL and OPG gene expression in osteoblastic cells. PMID: 21656335
    20. OPG gene transfer to periodontal tissues could inhibit relapse after orthodontic tooth movement, through the inhibition of osteoclastogenesis PMID: 22196183
    21. Omentin-1 ameliorates arterial calcification and bone loss in vivo through the regulation of the RANK signalling pathway in osteoprotegerin-deficient mice. PMID: 21750093
    22. Increased bone resorption is a noncell autonomous defect, caused by exuberant stimulation of osteo-clastogenesis by Cx43-deficient bone marrow stromal cells, via decreased Opg production. PMID: 21346198
    23. Osteoprotegerin serum levels were decreased in all IL-6 deficient mice and in a highest degree in sham-operated hypothyroid mice. PMID: 21478097
    24. TRAIL and osteoprotegerin are expressed in atherosclerotic plaques in a calcification-prone mouse model PMID: 21426505
    25. RANKL and OPG could have a close relationship with the osteoclast activity during mandibular first molar eruption. PMID: 18788552
    26. distribution of the osteocytic lacunar-canalicular system and osteocyte-secreting molecules--dentin matrix protein 1 and sclerostin--in the epiphyses and cortical bones in osteoprotegerin deficiency PMID: 21079361
    27. overexpression in preosteoblasts promotes their differentiation into mature osteoblasts PMID: 20936961
    28. Co2+ and Cr3+ can stimulate the mRNA expressions of RANKL and osteoprotegerin in osteoblasts. PMID: 20369527
    29. mechanical stretching may play an important role in bone remodeling through the upregulation of OPG and the mechanical signaling leading to OPG induction involves the noncanonical Wnt pathway. PMID: 20200998
    30. Osteoprotegerin(OPG) ex vivo gene therapy may be useful to treat patients for aseptic loosening of prosthetic implants. PMID: 11918293
    31. expression of RANKL and osteoprotegerin mRNAs by marrow stromal cells PMID: 12211438
    32. Osteosclerosis in mice with thrombopoietin overexpression occurs predominantly via up-regulation of osteoprotegerin in host stromal cells leading to disruption of osteoclastogenesis. PMID: 12506018
    33. The presence of OPG on the membrane of these cells was confirmed by western blotting and immunostaining, sRANKL was found to be bound to the OPG on the osteoclast precursors. PMID: 12526098
    34. expression of RANKL and OPG change with age in whole bone and in cultured osteoblast-like cells PMID: 12568404
    35. Runx2 promotes osteoclast differentiation by inducing RANKL and inhibiting OPG PMID: 12697767
    36. osteoprotegerin and RANK ligand have roles in breast cancer bone metastasis PMID: 12923331
    37. bone formation is coupled with bone resorption at local sites in OPG-/- mice, and that serum RANKL levels do not reflect this coupling. PMID: 14500574
    38. OPG secretion is regulated through calmodulin-sensitive protein kinase signaling that depends on the activity of the L-type VSCC and is mediated through the cAMP response element-binding protein. PMID: 14525906
    39. suppression of gene expression affects osteoclastogenic activity of parathyroid hormone PMID: 14969393
    40. Expression in mice with collagen-induced arthritis treated with Kanzo-bushi-to, a Kampo medicine. PMID: 15340228
    41. expression of RANKL and OPG and the formation of osteoclast-like cells do not require Runx2 PMID: 15474477
    42. RANKL inhibitor osteoprotegerin is used to evaluate the role of osteoclast-mediated hypercalcemia in two murine models of hypercalcemia of malignancy. PMID: 15845617
    43. Microorganism-reactive CD4+ T-cells and the RANKL-osteoprotegerin axis provide the molecular basis of the advanced periodontal breakdown in diabetes. PMID: 15855336
    44. findings in OPG knockout mice support the hypothesis that OPG is important in the inhibition of bone remodeling within the otic capsule and the maintenance of normal auditory function PMID: 16467704
    45. Glucocorticoids regulate osteoclast differentiation and expression of receptor activator of nuclear factor-kappaB (NF-kappaB) ligand, osteoprotegerin, and receptor activator of NF-kappaB in mouse calvarial bones PMID: 16614077
    46. OPG inhibits advanced plaque progression by preventing an increase in lesion size and lesion calcification. OPG may act as a survival factor and may modulate MMP9 production in vascular cells. PMID: 16840715
    47. microgravity is capable to indirectly stimulate osteoclast formation and activity by regulating osteoblast secretion of crucial regulatory factors such as RANKL and OPG PMID: 16927271
    48. Altogether, these findings suggest that increased OPG production represents an early event in the natural history of diabetes mellitus, possibly contributing to disease-associated endothelial cell dysfunction. PMID: 17148684
    49. OPG suppresses the shedding of RANKL from osteoblasts and the serum RANKL in OPG(-/-) mice exactly reflects the state of bone resorption. PMID: 17182555
    50. bone resorptive action of Dexamethasone is mediated mainly by the inhibition of OPG by transrepressing the OPG gene through the AP-1 site PMID: 17516544

    显示更多

    收起更多

  • 亚细胞定位：
    Secreted.
  • 组织特异性：
    Highly expressed in liver, lung, stomach, intestines and calvaria. Highly expressed in decidua and placenta, and in embryo.
  • 数据库链接：